CAS alert: Recall of Tredaptive® (nicotinic acid / laropiprant) modified-release tablets (Class 2 drug alert)

Source: CAS, MHRA Area: News The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) confirmed on Friday 18th January 2013 that it is recommending the suspension of the marketing authorisations of Tredaptive® (nicotinic acid / laropiprant) used to treat adults with dyslipidaemia, as its benefits no longer outweigh its risks (see link below for previous NeLM report).   Following on from this, the MHRA has now issued a Class 2 drug alert recalling all unexpired stock of Tredaptive® modified-release tablets, which has been supplied both as originator and parallel-distributed product. All stock is affected by the recall, irrespective of batch number, expiry date and pack size.   The alert states that no further Tredaptive® tablets should be dispensed and pharmacists should refer patients with new or repeat prescriptions to the treating physician to review their treatment plan on a non-urgent basis.   Please see the full alert at the link below for ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news